Form 4: Supernus Pharmaceuticals Executive Awarded Performance Share Units

Sentiment:

SEC Form 4 Filing


Frank Mottola, SVP at Supernus Pharmaceuticals, reports acquisition of performance share units.

Summary

  • Frank Mottola, a Senior Vice President at Supernus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
  • On February 5, 2025, Mottola acquired 3,750 performance share units (PSUs) and 2,010 PSUs, which convert into common stock.
  • These PSUs were awarded on February 22, 2024, and February 22, 2022, respectively, and vested upon achievement of individual performance objectives.
  • Following the reported transactions, Mottola directly owns 8,451 shares of common stock and 5,760 performance share units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future performance.

Stakeholder Impact

  • The acquisition of performance share units by a company executive can be viewed positively by shareholders as it aligns management's interests with the company's performance.

Key Dates

DateDescription
May 3, 2022Date objectives were established for PSUs awarded on February 22, 2022.
February 22, 2022Reporting Person was awarded Performance Share Units, portions of which vested upon the achievement of individual performance objectives within defined performance periods.
June 24, 2024Date objectives were established for PSUs awarded on February 22, 2024.
February 22, 2024Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period.
February 5, 2025Date of transaction: acquisition of performance share units.
February 6, 2025Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.